European Medicines Agency (EMA)/European Society for Medical Oncology (ESMO) Rare Cancers Europe initiative: Joint workshop on chordoma as a model for very rare cancers

Date: 30/04/2015
Location: European Medicines Agency, London, UK
Following the workshop on the methodology of clinical trials in rare cancers held in October 2014, the European Medicines Agency (EMA) and the European Society for Medical Oncology (ESMO) Rare Cancers Europe initiative will review a real case scenario on one single rare cancer and discuss together how to facilitate the development of promising therapies in spite of rarity. The aim of this workshop, which focuses on chordoma, is to discuss scientific and regulatory evidence requirements for rare diseases, main challenges and identify possible methodological solutions that could work for this and other very rare cancers. The meeting foresees the participation of oncologists, statisticians, methodologists, patient advocates and industry. A meeting report will be published on the EMA and ESMO websites. Registration by invitation only. Places limited.

How useful was this page?

Add your rating